These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24670388)

  • 1. Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction.
    Brantley SJ; Gufford BT; Dua R; Fediuk DJ; Graf TN; Scarlett YV; Frederick KS; Fisher MB; Oberlies NH; Paine MF
    CPT Pharmacometrics Syst Pharmacol; 2014 Mar; 3(3):e107. PubMed ID: 24670388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers.
    Gufford BT; Barr JT; González-Pérez V; Layton ME; White JR; Oberlies NH; Paine MF
    CPT Pharmacometrics Syst Pharmacol; 2015 Dec; 4(12):701-10. PubMed ID: 26904384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors.
    Brantley SJ; Graf TN; Oberlies NH; Paine MF
    Drug Metab Dispos; 2013 Sep; 41(9):1662-70. PubMed ID: 23801821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
    Brantley SJ; Oberlies NH; Kroll DJ; Paine MF
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1081-7. PubMed ID: 19934397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
    Chen KF; Chan LN; Lin YS
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
    Han B; Mao J; Chien JY; Hall SD
    Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
    Machavaram KK; Endo-Tsukude C; Terao K; Gill KL; Hatley OJ; Gardner I; Parrott N; Ducray PS
    AAPS J; 2019 Mar; 21(3):42. PubMed ID: 30887238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Br J Clin Pharmacol; 2020 Oct; 86(10):2080-2094. PubMed ID: 32250458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
    Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
    Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.
    Ke AB; Nallani SC; Zhao P; Rostami-Hodjegan A; Unadkat JD
    CPT Pharmacometrics Syst Pharmacol; 2012 Sep; 1(9):e3. PubMed ID: 23835883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.
    Lilja JJ; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):833-9. PubMed ID: 17392729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
    Morcos PN; Chang L; Kulkarni R; Giraudon M; Shulman N; Brennan BJ; Smith PF; Tran JQ
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1939-49. PubMed ID: 23872824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
    Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
    Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.